A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma

Cancer vaccines as immunotherapy for solid tumours are currently in development with promising results. We report a phase 1 study of Ad-sig-hMUC1/ecdCD40L (NCT02140996), an adenoviral-vector vaccine encoding the tumour-associated antigen MUC1 linked to CD40 ligand, in patients with advanced adenocar...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Tira J., Ang, W. X. Gladys, Wang, Who-Whong, Chong, Hui-Shan, Tan, Sze Huey, Cheong, Rachael, Chia, John Whay-Kuang, Syn, Nicholas L., Shuen, Wai Ho, Ba, Rebecca, Kaliaperumal, Nivashini, Au, Bijin, Hopkins, Richard, Li, Xinhua, Tan, Aaron C., Seet, Amanda O. L., Connolly, John E., Arkachaisri, Thaschawee, Chew, Valerie, Lajam, Ahmad bin Mohamed, Guo, Dianyan, Chew, Marvin Z. W., Wasser, Martin, Kumar, Pavanish, Albani, Salvatore, Toh, Han Chong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616917/
https://www.ncbi.nlm.nih.gov/pubmed/36307410
http://dx.doi.org/10.1038/s41467-022-33834-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616917/
https://www.ncbi.nlm.nih.gov/pubmed/36307410
http://dx.doi.org/10.1038/s41467-022-33834-4

Ejemplares similares